An RYR2-interacting fragment of MYBPC3 mitigates arrhythmia in human iPSC-CM and mouse models of CPVT
Molecular Therapy · 2026-08 · 34 (8) · 4502-4517
DOI: 10.1016/j.ymthe.2026.04.030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026-08. Verfasst von Fujian Lu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA. Electronic address: fujianlu@fudan.edu.cn. Hauptthemen laut MEDLINE: Ryanodine Receptor Calcium Release Channel, Myocytes, Cardiac, Tachycardia, Ventricular, Carrier Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, National Heart Lung and Blood Institute, American Heart Association Inc.
Abstract (Originalsprache)
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia caused by pathogenic variants in RYR2 that increase its diastolic Ca 2+ release. Current standard of care is insufficient to protect patients from ventricular tachycardia (VT) and sudden death. We identified RYR2 interaction with a subset of MYBPC3 in cardiomyocytes, and validated this interaction by immunostaining, proximity ligation assay, and co-immunoprecipitation. Adeno-associated virus serotype 9 (AAV9)-mediated MYBPC3 overexpression reduced VT in Ryr2 R176Q/+ mice, a model of CPVT. We identified a C-terminal fragment of MYBPC3, C6C10Δ, that is sufficient for RYR2 interaction and anti-arrhythmic activity. Recombinant C6C10Δ reduced the open probability of RYR2-R176Q channels in lipid bilayer single channel recordings, and virally delivered C6C10Δ reduced VT inducibility and duration in the CPVT mouse model and in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) harboring several different CPVT-causing RYR2 variants. In wild-type mice, MyoAAV4E-C6C10Δ did not detectably affect cardiac morphology or systolic function. However, a proportion of MyoAAV4E-C6C10Δ-treated wild-type mice exhibited inducible VT, suggesting proarrhythmic potential that warrants further study. Together, these findings demonstrate that a subset of MYBPC3 interacts with RYR2, and that this interaction may be therapeutically exploited to develop CPVT gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA. Electronic address: fujianlu@fudan.edu.cn.
- Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA.
- Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA. Electronic address: vassilios.bezzerides@cardio.chboston.org.
- Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA. Electronic address: william.pu@cardio.chboston.org.
Förderung
- NHLBI NIH HHS
- National Heart Lung and Blood Institute
- American Heart Association Inc
- National Institutes of Health
- Sarepta Therapeutics Inc
Zitieren
APA
Lu, F., Wu, Z., Chi, S., Li, J., Ponek, A., Liou, C., Ma, Q., Bonde, D., Pavlaki, N., Sweat, M. E., Shafaattalab, S., Tharani, Y., Prondzynski, M., Bezzerides, V. J., & Pu, W. T. (2026). An RYR2-interacting fragment of MYBPC3 mitigates arrhythmia in human iPSC-CM and mouse models of CPVT. Molecular Therapy, 34(8), 4502-4517. https://doi.org/10.1016/j.ymthe.2026.04.030
Vancouver
Lu F, Wu Z, Chi S, Li J, Ponek A, Liou C, et al. An RYR2-interacting fragment of MYBPC3 mitigates arrhythmia in human iPSC-CM and mouse models of CPVT. Molecular Therapy. 2026;34(8):4502-4517. doi:10.1016/j.ymthe.2026.04.030
BibTeX
@article{Lu2026,
author = {Lu, Fujian and Wu, Zexuan and Chi, Shaopeng and Li, Jiajin and Ponek, Anna and Liou, Carter and Ma, Qing and Bonde, Durgesh and Pavlaki, Nikoleta and Sweat, Mason E and Shafaattalab, Sanam and Tharani, Yashasvi and Prondzynski, Maksymilian and Bezzerides, Vassilios J and Pu, William T},
title = {An RYR2-interacting fragment of MYBPC3 mitigates arrhythmia in human iPSC-CM and mouse models of CPVT},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {8},
pages = {4502--4517},
doi = {10.1016/j.ymthe.2026.04.030}
}
EUVIMED